Comparative Pharmacology
Head-to-head clinical analysis: GLIADEL versus MUSTARGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLIADEL versus MUSTARGEN.
GLIADEL vs MUSTARGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GLIADEL (carmustine implant) is a biodegradable wafer that delivers carmustine, a nitrosourea alkylating agent, directly into the tumor resection cavity. Carmustine alkylates DNA and RNA, leading to cross-linking and inhibition of DNA replication, ultimately causing cell death. It is cell cycle phase nonspecific.
MUSTARGEN (mechlorethamine HCl) is a nitrogen mustard alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription, leading to cell death.
Gliadel (carmustine) implant is administered intraoperatively as 8 wafers, each containing 7.7 mg carmustine, placed in the resection cavity after tumor debulking. Maximum dose is 61.6 mg (8 wafers).
IV: 0.4 mg/kg or 12 mg/m² BSA as a single dose or divided into 0.1 mg/kg/day for 4 days.
None Documented
None Documented
Terminal elimination half-life is approximately 1.3 hours for the active dianhydrogalactitol metabolite. Clinical context: short half-life supports local interstitial delivery with minimal systemic accumulation.
Terminal half-life: 30-60 minutes (rapidly inactivated); clinical context: very short due to rapid hydrolysis and alkylation, necessitating rapid administration after reconstitution.
Primarily renal (60-70% as unchanged drug and metabolites) and biliary/fecal (15-20%). Approximately 10-15% is eliminated via exhaled air as CO2.
Renal: 50% as unchanged drug and metabolites; fecal: minor (<10%); biliary: minimal.
Category C
Category C
Alkylating Agent
Alkylating Agent